8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 24, 2026·SEC
Neurogene Inc.(NGNE)Earnings, Financials & Key Ratios
NGNE•NASDAQ
Price updated Jun 19, 2026
AboutNeurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.Show more
- Revenue$0-100.0%
- EBITDA-$103M-30.2%
- Net Income-$90M-20.2%
- EPS (Diluted)-4.24+0.9%
- ROE-31.41%-3.8%
NGNE Key Insights
Neurogene Inc. (NGNE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
✗Weaknesses
- ✗Profits declining 22.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 20.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NGNE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NGNE Price & Volume
Neurogene Inc. (NGNE) stock price & volume — 10-year historical chart
Loading chart...
NGNE Growth Metrics
Neurogene Inc. (NGNE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.71%
Return on Capital
10 Years-34.2%
5 Years-39.26%
3 Years-34.46%
Last Year-34.82%
NGNE Recent Earnings
Neurogene Inc. (NGNE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$1.39-7.2%
$1.30
Rev
—
—
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$1.12+9.6%
$1.24
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.99+21.4%
$1.26
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.05+8.7%
$1.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $1.39vs $1.30-7.2% | — |
| Q2 2026 | Mar 24, 2026 | $1.12vs $1.24+9.6% | — |
| Q4 2025 | Nov 13, 2025 | $0.99vs $1.26+21.4% | — |
| Q3 2025 | Aug 11, 2025 | $1.05vs $1.15+8.7% | — |
Based on last 12 quarters of dataView full earnings history →
NGNE Peer Comparison
Neurogene Inc. (NGNE) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% |
Compare NGNE vs Peers
Neurogene Inc. (NGNE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NGNE Income Statement
Neurogene Inc. (NGNE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 25M | 0 | 0 | 0 | 0 | 0 | 925K | 0 | 0 |
Revenue Growth % | - | - | -100% | - | - | - | - | - | -100% | -100% |
Cost of Goods Sold | 0 | 0 | 340K | 1.82M | 42.26M | 3.2M | 3.26M | 3.25M | 3.19M | 1.64M |
COGS % of Revenue | - | - | - | - | - | - | - | 351.03% | - | - |
Gross Profit | 0▲ 0% | 25M▲ 0% | -340K▼ 101.4% | -1.82M▼ 435.6% | -42.26M▼ 2220.9% | -3.2M▲ 92.4% | -3.26M▼ 2.1% | -2.32M▲ 28.8% | -3.19M▼ 37.5% | -1.64M▲ 0% |
Gross Margin % | - | 100% | - | - | - | - | - | -251.03% | - | - |
Gross Profit Growth % | - | - | -101.36% | -435.59% | -2220.92% | 92.44% | -2.07% | 28.82% | -37.47% | - |
Operating Expenses | 51.12M | 48.52M | 24.1M | 39.73M | 8.27M | 53.32M | 52.32M | 80.28M | 100.02M | 109.12M |
OpEx % of Revenue | - | 194.1% | - | - | - | - | - | 8679.24% | - | - |
Selling, General & Admin | 14.85M | 15.73M | 17.79M | 15.39M | 8.27M | 9.01M | 11.19M | 22.61M | 25.13M | 27.57M |
SG&A % of Revenue | - | 62.94% | - | - | - | - | - | 2444.65% | - | - |
Research & Development | 36.27M | 32.79M | 6.32M | 24.34M | 42.26M | 47.51M | 44.39M | 60.92M | 75.01M | 82.4M |
R&D % of Revenue | - | 131.16% | - | - | - | - | - | 6585.62% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -42.26M | -3.2M | -3.26M | -3.25M | 0 | -854K |
Operating Income | -51.12M▲ 0% | -23.52M▲ 54.0% | -24.44M▼ 3.9% | -41.55M▼ 70.0% | -50.53M▼ 21.6% | -56.52M▼ 11.8% | -55.58M▲ 1.7% | -82.61M▼ 48.6% | -103.21M▼ 24.9% | -110.76M▲ 0% |
Operating Margin % | - | -94.1% | - | - | - | - | - | -8930.27% | - | - |
Operating Income Growth % | -35.79% | 53.98% | -3.91% | -70% | -21.61% | -11.84% | 1.65% | -48.62% | -24.94% | - |
EBITDA | -50.18M | -31.58M | -24.1M | -39.73M | -49.59M | -53.32M | -52.29M | -79.36M | -103.33M | -107.57M |
EBITDA Margin % | - | -126.32% | - | - | - | - | - | -8579.24% | - | - |
EBITDA Growth % | -35.62% | 37.06% | 23.68% | -64.85% | -24.8% | -7.53% | 1.94% | -51.78% | -30.2% | -24.27% |
D&A (Non-Cash Add-back) | 0 | 0 | 340K | 1.82M | 947K | 3.2M | 3.3M | 3.25M | 0 | 3.18M |
EBIT | -50.18M | -31.58M | -69.44M | -33.28M | -50.53M | -55.19M | -55.58M | -75.13M | -103.21M | -103.84M |
Net Interest Income | 994K | 1.56M | 1.54M | 490K | 19K | 1.33M | 2.94M | 8.46M | 11.54M | 10.6M |
Interest Income | 998K | 1.56M | 1.54M | 490K | 19K | 1.34M | 2.95M | 8.47M | 11.55M | 10.6M |
Interest Expense | 4K | 4K | 1K | 0 | 0 | 2K | 12K | 12K | 5K | 3K |
Other Income/Expense | 936K | -8.06M | -45M | 8.28M | 17K | 1.33M | 19.27M | 7.46M | 12.86M | 12.12M |
Pretax Income | -50.18M▲ 0% | -31.59M▲ 37.1% | -69.44M▼ 119.9% | -33.28M▲ 52.1% | -50.52M▼ 51.8% | -55.19M▼ 9.2% | -36.32M▲ 34.2% | -75.14M▼ 106.9% | -90.35M▼ 20.2% | -98.64M▲ 0% |
Pretax Margin % | - | -126.34% | - | - | - | - | - | -8123.68% | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -50.18M▲ 0% | -31.59M▲ 37.1% | -69.44M▼ 119.9% | -33.28M▲ 52.1% | -50.52M▼ 51.8% | -55.19M▼ 9.2% | -36.32M▲ 34.2% | -75.14M▼ 106.9% | -90.35M▼ 20.2% | -98.64M▲ 0% |
Net Margin % | - | -126.34% | - | - | - | - | - | -8123.68% | - | - |
Net Income Growth % | -35.62% | 37.06% | -119.86% | 52.08% | -51.81% | -9.25% | 34.2% | -106.91% | -20.24% | -21.97% |
Net Income (Continuing) | -50.18M | -31.59M | -69.44M | -33.28M | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M | -98.64M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.14▲ 0% | -1.34▲ 37.4% | -2.57▼ 91.8% | -0.64▲ 75.1% | -0.92▼ 43.8% | -4.30▼ 367.4% | -2.83▲ 34.2% | -4.28▼ 51.2% | -4.24▲ 0.9% | -4.42▲ 0% |
EPS Growth % | -9.18% | 37.38% | -91.79% | 75.1% | -43.75% | -367.39% | 34.19% | -51.24% | 0.93% | -7.71% |
EPS (Basic) | -2.14 | -1.34 | -2.57 | -0.64 | -0.92 | -4.30 | -2.83 | -4.28 | -4.24 | - |
Diluted Shares Outstanding | 23.45M | 23.52M | 27.03M | 51.83M | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M | 22.31M |
Basic Shares Outstanding | 23.45M | 23.52M | 27.03M | 51.83M | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M | 22.31M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NGNE Balance Sheet
Neurogene Inc. (NGNE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 108.83M | 77.17M | 143.6M | 194.52M | 73.96M | 84.72M | 200.35M | 315.92M | 271.77M | 246.75M |
Cash & Short-Term Investments | 108.08M | 76.93M | 143.09M | 192.56M | 70.54M | 82.02M | 197.16M | 312.4M | 269.01M | 243.18M |
Cash Only | 52.03M | 76.93M | 143.09M | 192.56M | 70.54M | 82.02M | 148.21M | 136.59M | 103.84M | 124.16M |
Short-Term Investments | 56.05M | 0 | 0 | 0 | 0 | 0 | 48.95M | 175.82M | 165.17M | 119.02M |
Accounts Receivable | 0 | 0 | 0 | 0 | 790K | 0 | 600K | 648K | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | 255.7 | - | - |
Inventory | 0 | 0 | 0 | 0 | 1.91M | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | 16.52 | - | - | - | - | - |
Other Current Assets | 740K | 237K | 503K | 1.97M | -1.2M | 1.62M | 1.09M | 981K | 2.76M | 3.56M |
Total Non-Current Assets | 1.5M | 453K | 3.43M | 16M | 27.53M | 24.55M | 22.23M | 19.81M | 16.83M | 16.39M |
Property, Plant & Equipment | 905K | 400K | 2.83M | 13.72M | 27.53M | 24.55M | 20.95M | 18.49M | 15.46M | 14.98M |
Fixed Asset Turnover | - | 62.50x | - | - | - | - | - | 0.05x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 567K | 347K | 128K | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 878K | 0 | 0 | 0 | 0 | 339K |
Other Non-Current Assets | 599K | 53K | 30K | 1.93M | -1.01M | 0 | 1.27M | 1.31M | 1.37M | 1.42M |
Total Assets | 110.33M▲ 0% | 77.62M▼ 29.6% | 147.02M▲ 89.4% | 210.52M▲ 43.2% | 101.49M▼ 51.8% | 109.27M▲ 7.7% | 222.57M▲ 103.7% | 335.73M▲ 50.8% | 288.6M▼ 14.0% | 263.14M▲ 0% |
Asset Turnover | - | 0.32x | - | - | - | - | - | 0.00x | - | 0.00x |
Asset Growth % | -28.53% | -29.65% | 89.42% | 43.19% | -51.79% | 7.66% | 103.7% | 50.84% | -14.04% | 110.31% |
Total Current Liabilities | 10.96M | 4.63M | 4.74M | 7.89M | 10.86M | 6.65M | 22.97M | 15.16M | 16.41M | 18.87M |
Accounts Payable | 0 | 702K | 1.6M | 1.32M | 5.63M | 625K | 2.6M | 1.34M | 1.95M | 4.68M |
Days Payables Outstanding | - | - | 1.72K | 265.18 | 48.62 | 71.38 | 290.48 | 150.18 | 223.32 | 569.52 |
Short-Term Debt | 0 | 0 | 618K | 708K | 1.22M | 0 | 0 | 3M | 3.06M | 3.05M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9.4M | 3.92M | 1.28M | 2.61M | 132K | 167K | 6.71M | 1.43M | 11.39M | 11.13M |
Current Ratio | 9.93x | 16.68x | 30.28x | 24.66x | 6.81x | 12.74x | 8.72x | 20.84x | 16.56x | 13.08x |
Quick Ratio | 9.93x | 16.68x | 30.28x | 24.66x | 6.64x | 12.74x | 8.72x | 20.84x | 16.56x | 13.08x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 486K | 319K | 593K | 11.41M | 182.51M | 3.99M | 13.58M | 10.2M | 7.31M | 6.49M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.83M | 6.08M |
Capital Lease Obligations | 33K | 6K | 593K | 11.41M | 4.6M | 3.99M | 13.37M | 9.43M | 0 | 22.93M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 572K |
Other Non-Current Liabilities | 0 | -1 | 0 | 0 | 177.91M | 0 | 203K | 769K | 479K | 409K |
Total Liabilities | 11.44M | 4.95M | 5.34M | 19.3M | 193.36M | 10.64M | 36.55M | 25.36M | 23.72M | 25.36M |
Total Debt | 33K | 6K | 1.21M | 12.12M | 6.43M | 4.69M | 16.25M | 12.43M | 9.89M | 9.13M |
Net Debt | -52M | -76.92M | -141.88M | -180.43M | -64.11M | -77.33M | -131.96M | -124.16M | -93.95M | -115.03M |
Debt / Equity | 0.00x | 0.00x | 0.01x | 0.06x | - | 0.05x | 0.09x | 0.04x | 0.04x | 0.04x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.08x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.07x |
Interest Coverage | -12544.75x | -7895.25x | -69441.00x | - | - | -27593.50x | -4631.92x | -6261.00x | -20641.60x | -34615.00x |
Total Equity | 98.89M▲ 0% | 72.67M▼ 26.5% | 141.69M▲ 95.0% | 191.22M▲ 35.0% | -91.88M▼ 148.0% | 98.63M▲ 207.3% | 186.02M▲ 88.6% | 310.38M▲ 66.8% | 264.89M▼ 14.7% | 237.78M▲ 0% |
Equity Growth % | -31.64% | -26.51% | 94.97% | 34.96% | -148.05% | 207.35% | 88.61% | 66.85% | -14.66% | 136.35% |
Book Value per Share | 4.22 | 3.09 | 5.24 | 3.69 | -1.67 | 7.69 | 14.51 | 17.67 | 12.51 | 10.66 |
Total Shareholders' Equity | 98.89M | 72.67M | 141.69M | 191.22M | -91.88M | 98.63M | 186.02M | 310.38M | 264.89M | 237.78M |
Common Stock | 0 | 0 | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -198.5M | -230.09M | -299.53M | -332.81M | -95.65M | -150.84M | -187.15M | -262.3M | -352.65M | -383.58M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -70K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NGNE Cash Flow Statement
Neurogene Inc. (NGNE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -44.72M | -31.58M | -15.39M | -24.57M | -46.4M | -52.82M | -51.42M | -70.6M | -77.17M | -81.94M |
Operating CF Margin % | - | -126.31% | - | - | - | - | - | -7632.76% | - | - |
Operating CF Growth % | -47.95% | 29.39% | 51.25% | -59.64% | -88.81% | -13.84% | 2.65% | -37.3% | -9.31% | -69.95% |
Net Income | -50.18M | -31.59M | -8.1M | -33.28M | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M | -98.64M |
Depreciation & Amortization | 0 | 0 | 340K | 1.82M | 947K | 3.2M | 3.3M | 3.25M | 3.09M | 3.22M |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 896K | 1.25M | 1.42M | 8.32M | 14.18M | 3.41M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | -105K | 0 | 0 | 0 |
Other Non-Cash Items | 4.55M | 5.44M | -5.68M | 5.92M | 679K | 608K | -15.69M | -1.06M | -4.37M | 7.18M |
Working Capital Changes | 917K | -5.43M | -1.95M | 966K | 1.59M | -2.69M | -4.02M | -5.96M | 268K | 2.89M |
Change in Receivables | 0 | 0 | 290K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 2.98M | -3.61M | 667K | -77K | 627K | 1.34M |
Cash from Investing | 64.01M | 55.95M | -688K | -2.22M | -18.37M | -2.23M | 25.64M | -125.26M | 14M | 106.01M |
Capital Expenditures | -494K | -49K | -879K | -2.22M | -18.37M | -2.23M | -321K | -808K | -1.18M | -669.4K |
CapEx % of Revenue | - | 0.2% | - | - | - | - | - | 87.35% | - | - |
Acquisitions | 0 | 0 | 191K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 20.96M | 0 | 0 | 0 |
Cash from Financing | 423K | 570K | 82.24M | 77.14M | 51.06M | 66.53M | 92.48M | 184.07M | 30.43M | 30.68M |
Debt Issued (Net) | -15K | -32K | -9K | -49K | 0 | -1K | -29K | -52K | -61K | -51.59K |
Equity Issued (Net) | 438K | 602K | 82.25M | 77.18M | 50.78M | 66.46M | 92.34M | 189.59M | 30.49M | 30.73M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 287K | 73K | 168K | -5.47M | 0 | -1.59K |
Net Change in Cash | 19.73M▲ 0% | 24.9M▲ 26.2% | 66.17M▲ 165.8% | 49.46M▼ 25.2% | -13.71M▼ 127.7% | 11.48M▲ 183.7% | 66.7M▲ 481.1% | -11.79M▼ 117.7% | -32.74M▼ 177.6% | 53.39M▲ 0% |
Free Cash Flow | -45.21M▲ 0% | -31.63M▲ 30.0% | -16.27M▲ 48.5% | -26.79M▼ 64.7% | -64.77M▼ 141.7% | -55.05M▲ 15.0% | -51.74M▲ 6.0% | -71.41M▼ 38.0% | -78.36M▼ 9.7% | -82.61M▲ 0% |
FCF Margin % | - | -126.5% | - | - | - | - | - | -7720.11% | - | - |
FCF Growth % | -46.13% | 30.05% | 48.55% | -64.65% | -141.73% | 15% | 6.01% | -38.01% | -9.73% | -15.94% |
FCF per Share | -1.93 | -1.34 | -0.60 | -0.52 | -1.18 | -4.29 | -4.03 | -4.07 | -3.70 | -3.70 |
FCF Conversion (FCF/Net Income) | 0.89x | 1.00x | 0.22x | 0.74x | 0.92x | 0.96x | 1.42x | 0.94x | 0.85x | 0.84x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 2K | 0 | 0 | 0 | 1K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NGNE Key Ratios
Neurogene Inc. (NGNE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -41.21% | -36.82% | -64.79% | -19.99% | -101.7% | -1634.75% | -25.52% | -30.28% | -31.41% | -37.88% |
Return on Invested Capital (ROIC) | -48.14% | -82.76% | - | -588.75% | - | - | -110.63% | -51.57% | -43.35% | -45.72% |
Gross Margin | - | 100% | - | - | - | - | - | -251.03% | - | - |
Net Margin | - | -126.34% | - | - | - | - | - | -8123.68% | - | - |
Debt / Equity | 0.00x | 0.00x | 0.01x | 0.06x | - | 0.05x | 0.09x | 0.04x | 0.04x | 0.04x |
Interest Coverage | -12544.75x | -7895.25x | -69441.00x | - | - | -27593.50x | -4631.92x | -6261.00x | -20641.60x | -34615.00x |
FCF Conversion | 0.89x | 1.00x | 0.22x | 0.74x | 0.92x | 0.96x | 1.42x | 0.94x | 0.85x | 0.84x |
Revenue Growth | - | - | -100% | - | - | - | - | - | -100% | -100% |
Related:NGNE Dividend History·NGNE Revenue History·NGNE Price History·NGNE P/E History·NGNE Financial Ratios·NGNE Institutional Holders
NGNE SEC Filings & Documents
Neurogene Inc. (NGNE) SEC filings — annual & quarterly reports (10-K, 10-Q)
NGNE Frequently Asked Questions
Neurogene Inc. (NGNE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Neurogene Inc. (NGNE) saw revenue decline by 100.0% over the past year.
Neurogene Inc. (NGNE) reported a net loss of $98.6M for fiscal year 2025.
Dividend & Returns
Neurogene Inc. (NGNE) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.
Neurogene Inc. (NGNE) had negative free cash flow of $82.6M in fiscal year 2025, likely due to heavy capital investments.